LAVA Therapeutics (LVTX) has released an update.
LAVA Therapeutics reports a significant reduction in operating losses, posting a loss of $553,000 for the three months ended March 31, 2024, compared to a loss of $13.94 million in the same period the previous year. The company’s gross profit surged to $6.99 million, up from $294,000, while total assets slightly decreased to $99.08 million from $101.71 million year-over-year. Despite the improved performance, the company experienced a comprehensive loss of $1.62 million, influenced by a foreign currency translation adjustment.
For further insights into LVTX stock, check out TipRanks’ Stock Analysis page.
